# Association of IL6 Gene Polymorphisms with COVID-19 Susceptibility and Inflammation in Pregnant Women

**Authors:** Imene Ben Dhifallah, Kaouther Ayouni, Ghassen Kharroubi, Zeineb Belaiba, Majdi Ben Ameur, Henda Touzi, Walid Hammemi, Nesrine Abderahmane, Amel Sadraoui, Khaoula Magdoud, Hiba Mkadmi, Samia Kacem, Myriam Cheour, Hajer Chourou, Rim Ben Hmid, Youssef Atef, Khaled Neji, Mohamed Bedis Channoufi, Emna Barkaoui, Dalenda Chelli, Henda Triki, Mariem Gdoura

PMC · DOI: 10.3390/diseases14020048 · 2026-01-30

## TL;DR

This study investigates whether genetic variations in the IL6 gene affect the risk of COVID-19 and inflammation levels in pregnant women, but finds no significant associations.

## Contribution

The study explores IL6 gene polymorphisms in pregnant women, revealing no link to COVID-19 susceptibility or IL-6 levels.

## Key findings

- No significant association was found between IL6 polymorphisms and COVID-19 susceptibility or IL-6 levels.
- Higher IL-6 levels (>5 pg/mL) were more common in SARS-CoV-2-negative pregnant women.
- Vaccinated SARS-CoV-2-negative women had significantly higher IL-6 levels compared to vaccinated positive women.

## Abstract

Background/Objectives: Pregnancy is characterized by complex immunological adaptations that may increase susceptibility to infections, including SARS-CoV-2. Interleukin-6 (IL-6), a key pro-inflammatory cytokine, plays a crucial role in the immune response and has been strongly implicated in the pathogenesis of COVID-19. Genetic variations in the IL6 gene, particularly single-nucleotide polymorphisms (SNPs) in the promoter region, can modulate IL-6 expression and potentially influence individual susceptibility to viral infections. This study aimed to evaluate the relationship between promoter region IL6 gene polymorphisms and COVID-19 susceptibility, as well as the inflammatory response, in pregnant women. Methods: We enrolled in this study 204 pregnant women with evidence of SARS-CoV-2 infection in pregnancy and 134 pregnant women with no evidence of SARS-CoV-2 infection in the past. Genotyping was conducted for the two functional SNPs in the IL6 promoter region, rs1800796 and rs1800797, via Sanger sequencing, and for associations with COVID-19 susceptibility and IL-6 levels were analyzed. Results: No significant association was found between IL6 polymorphisms and COVID-19, IL-6 levels, age, or immunization status. IL-6 levels > 5 pg/mL were more frequent in SARS-CoV-2-negative pregnant women than in SARS-CoV-2-positive pregnant women (p = 0.032). Among vaccinated participants, IL-6 levels were significantly higher in SARS-CoV-2-negative pregnant women (p = 0.044), while no difference was observed in the unvaccinated group. Conclusions:
IL6 polymorphisms rs1800797 and rs1800796 were not associated with infection susceptibility or IL-6 levels. These results highlight the complex immunological interplay between pregnancy, infection, and genetic background and support the need for further research in larger cohorts.

## Linked entities

- **Genes:** IL6 (interleukin 6) [NCBI Gene 3569]
- **Diseases:** COVID-19 (MONDO:0100096)

## Full-text entities

- **Genes:** ACE2 (angiotensin converting enzyme 2) [NCBI Gene 59272] {aka ACEH}, BSG (basigin (Ok blood group)) [NCBI Gene 682] {aka 5F7, CD147, EMMPRIN, EMPRIN, HAb18G, OK}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, NRP1 (neuropilin 1) [NCBI Gene 8829] {aka BDCA4, CD304, NP1, NRP, VEGF165R}, DPP4 (dipeptidyl peptidase 4) [NCBI Gene 1803] {aka ADABP, ADCP2, CD26, DPPIV, TP103}
- **Diseases:** COPD (MESH:D029424), pneumonia (MESH:D011014), cytokine storm (MESH:D000080424), obesity (MESH:D009765), neonatal complications (MESH:D007232), multi-organ dysfunction (MESH:D009102), tissue damage (MESH:D017695), infectious diseases (MESH:D003141), long COVID-19 (MESH:D000094024), SARS (MESH:D045169), storm (MESH:C566109), immune dysregulation (OMIM:614878), fever (MESH:D005334), ARDS (MESH:D012128), inflammatory and respiratory diseases (MESH:D012140), death (MESH:D003643), cervical cancer (MESH:D002583), lymphocyte dysfunction (MESH:D015451), viral infection (MESH:D014777), MERS (MESH:D018352), headache (MESH:D006261), Inflammation (MESH:D007249), respiratory infections (MESH:D012141), injury to (MESH:D014947), premature rupture of membranes (MESH:D005322), dry cough (MESH:D003371), preeclampsia (MESH:D011225), MAS (MESH:D055501), asthma (MESH:D001249), infected (MESH:D007239), dyspnea (MESH:D004417), preterm birth (MESH:D047928), lymphopenia (MESH:D008231), diabetes (MESH:D003920), COVID- (MESH:D000086382)
- **Chemicals:** oxygen (MESH:D010100), EDTA (MESH:D004492)
- **Species:** Severe acute respiratory syndrome coronavirus 2 (no rank) [taxon 2697049], Hepatitis B virus (no rank) [taxon 10407], Human immunodeficiency virus (species) [taxon 12721], Homo sapiens (human, species) [taxon 9606]
- **Mutations:** -597 G>A, -572 G>C, rs1474348, rs1800871, rs2069827, 174G/C, rs2069837, rs2066992

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12939677/full.md

---
Source: https://tomesphere.com/paper/PMC12939677